Floatz logo

Ruxolitinib Phosphate

Triple-Negative Breast Carcinoma

Mayo ClinicPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

448 Active assets in the Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Ruxolitinib Phosphate is also rated in:

mature T-cell and NK-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
B
Indicative ·
59 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →